NovAccess Global Inc. (OTCPK: XSNX)
Health Care · Biotechnology · US
$0.00
+100.00% today · -33.3% 1Y
NovAccess Global Inc. (OTCPK: XSNX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $12.33K and employs 2 people.
Over the last twelve months the share price has lost 33.3%, trading between 0.00 and 0.05.
Tweenvest scores NovAccess Global Inc. across four factors: quality 18/100. Its strongest factor is quality.
XSNX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $12.33K
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.06
- Dividend yield
- —
- Beta (5Y)
- 98.88
- 52-week high
- $0.05
- 52-week low
- $0.00
- Avg volume (3M)
- —
- Shares outstanding
- 61.65M
- Employees
- 2
- Next earnings
- —
About NovAccess Global Inc.
Operating as a biopharmaceutical firm, NovAccess Global Inc. focuses on developing innovative immunotherapies to treat individuals with brain tumors across the United States. Their primary expertise is in pioneering research that leverages a patient's own immune system to target and eliminate cancerous cells. The company, founded in 1997, has its headquarters situated in Chesterland, Ohio.
- ISIN
- US67001N1072
- Founded
- 1997
- Listed since
- Sep 21, 1998
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $263.45 | -0.57% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $440.67 | +0.31% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $145.57 | -0.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $547.80 | -0.05% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $824.34 | -1.16% |
| argenx SEENXTBR: ARGX | $65.85B | €867.40 | -3.84% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $137.35 | -5.33% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.